{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:14:49Z","timestamp":1792206889816,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/purpose<\/jats:title>\n                <jats:p>In axial spondyloarthritis (axSpA) inflammation of the sacroiliac joints and spine is associated with local extracellular matrix (ECM) remodeling of affected tissues. We aimed to investigate the association of ECM metabolites with treatment response in axSpA patients treated with TNF-\u03b1 inhibitory therapy for 46 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a prospective clinical study of axSpA patients (<jats:italic>n<\/jats:italic>=55) initiating a TNF inhibitor (infliximab, etanercept, or adalimumab), serum concentrations of formation of type I (PRO-C1), type III (PRO-C3), and type VI (PRO-C6) collagen; turnover of type IV collagen (PRO-C4), and matrix-metalloproteinase (MMP)-degraded type III (C3M) collagen, MMP-degraded type IV (C4M), type VI (C6M), and type VII (C7M) collagen, and cathepsin-degraded type X collagen (C10C), MMP-mediated metabolite of C-reactive protein (CRPM), citrullinated vimentin (VICM), and neutrophil elastase-degraded elastin (<jats:italic>EL<\/jats:italic>-<jats:italic>NE<\/jats:italic>) were measured at baseline, week 2, week 22, and week 46.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients were mostly males (82%), HLA-B27 positive (84%), with a median age of 40 years (IQR: 32\u201348), disease duration of 5.5 years (IQR: 2\u201310), and a baseline Ankylosing Spondylitis Disease Activity Score (ASDAS) of 3.9 (IQR: 3.0\u20134.5).<\/jats:p>\n                <jats:p>Compared to baseline, PRO-C1 levels were significantly increased after two weeks of treatment, C6M levels were significantly decreased after two and 22 weeks (repeated measures ANOVA, <jats:italic>p<\/jats:italic>=0.0014 and <jats:italic>p<\/jats:italic>=0.0015, respectively), EL-NE levels were significantly decreased after 2 weeks (<jats:italic>p<\/jats:italic>=0.0008), VICM levels were significantly decreased after two and 22 weeks (<jats:italic>p<\/jats:italic>=0.0163 and <jats:italic>p<\/jats:italic>=0.0374, respectively), and CRP were significantly decreased after two and 22 weeks (both <jats:italic>p<\/jats:italic>=0.0001). Baseline levels of PRO-C1, PRO-C3, C6M, VICM, and CRP were all associated with ASDAS clinically important and major improvement after 22 weeks (\u0394ASDAS \u22651.1) (Mann\u2013Whitney test, <jats:italic>p<\/jats:italic>=0.006, <jats:italic>p<\/jats:italic>=0.008, <jats:italic>p<\/jats:italic>&lt;0.001, &lt;0.001, &lt;0.001, respectively), while C6M, VICM and CRP levels were associated with ASDAS clinically important and major improvement after 46 weeks (\u0394ASDAS \u22652.0) (<jats:italic>p<\/jats:italic>=0.002, <jats:italic>p<\/jats:italic>=0.044, and <jats:italic>p<\/jats:italic>&lt;0.001, respectively). PRO-C1 and C6M levels were associated with a Bath AS Disease Activity Score (BASDAI) response to TNF-inhibitory therapy after 22 weeks (Mann\u2013Whitney test, <jats:italic>p<\/jats:italic>=0.020 and <jats:italic>p<\/jats:italic>=0.049, respectively). Baseline levels of PRO-C4 and C6M were correlated with the total SPARCC MRI Spine and Sacroiliac Joint Inflammation score (Spearman\u2019s Rho <jats:italic>\u03c1<\/jats:italic>=0.279, <jats:italic>p<\/jats:italic>=0.043 and <jats:italic>\u03c1<\/jats:italic>=0.496, <jats:italic>p<\/jats:italic>=0.0002, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Extracellular matrix metabolites were associated with ASDAS response, MRI inflammation, and clinical treatment response during TNF-inhibitory treatment in patients with axSpA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02967-8","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:04:51Z","timestamp":1671789891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Signe","family":"Holm Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Juul","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Kollerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorm","family":"Thamsborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Rintek","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Juhl","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"2967_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, Van Der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331.","journal-title":"Ann Rheum Dis"},{"key":"2967_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","volume":"41","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58\u201367.","journal-title":"Arthritis Rheum"},{"key":"2967_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/BOR.0000000000000180","volume":"27","author":"WP Maksymowych","year":"2015","unstructured":"Maksymowych WP. Biomarkers in axial spondyloarthritis. Curr Opin Rheumatol. 2015;27:343\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"2967_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"R Landew\u00e9","year":"2015","unstructured":"Landew\u00e9 R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015;17:47.","journal-title":"Curr Rheumatol Rep"},{"key":"2967_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2019.07.007","volume":"87","author":"F Proft","year":"2020","unstructured":"Proft F, Muche B, Spiller L, Rios Rodriguez V, Rademacher J, Weber AK, et al. Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. Jt Bone Spine. 2020;87:69\u201373.","journal-title":"Jt Bone Spine"},{"key":"2967_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2017-000586","volume":"4","author":"C Lukas","year":"2018","unstructured":"Lukas C, Cyteval C, Dougados M, Weber U. MRI for diagnosis of axial spondyloarthritis: Major advance with critical limitations \u201cNot everything that glisters is gold (standard).\u201d. RMD Open. 2018;4:1\u20139.","journal-title":"RMD Open"},{"key":"2967_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/ijms18040830","volume":"18","author":"S Moz","year":"2017","unstructured":"Moz S, Aita A, Basso D, Ramonda R, Plebani M, Punzi L. Spondyloarthritis: Matrix metalloproteinasesas biomarkers of pathogenesis and response to tumor necrosis factor (TNF) inhibitors. Int J Mol Sci. 2017;18:830.","journal-title":"Int J Mol Sci"},{"key":"2967_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13547500902777608","volume":"14","author":"MA Karsdal","year":"2009","unstructured":"Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14:181\u2013202.","journal-title":"Biomarkers."},{"key":"2967_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/978-94-007-7893-1_2","volume":"802","author":"M Mienaltowski","year":"2014","unstructured":"Mienaltowski M, Birk D. Structure, physiology, and biochemistry of collagens. Adv Exp Med Biol. 2014;802:5\u201329.","journal-title":"Adv Exp Med Biol"},{"key":"2967_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00296-021-04861-z","volume":"41","author":"S Holm Nielsen","year":"2021","unstructured":"Holm Nielsen S, Sardar S, Siebuhr A, Schlemmer A, Schmidt E, Bay-Jensen A, et al. Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Rheumatol Int. 2021;41:1065\u201377.","journal-title":"Rheumatol Int"},{"key":"2967_CR11","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2665-9913(20)30385-4","volume":"3","author":"R Dobrota","year":"2021","unstructured":"Dobrota R, Jordan S, Juhl P, Maurer B, Wildi L, Bay-Jensen AC, et al. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. Lancet Rheumatol. 2021;3:e175\u201384.","journal-title":"Lancet Rheumatol"},{"key":"2967_CR12","doi-asserted-by":"publisher","first-page":"e00217","DOI":"10.14309\/ctg.0000000000000217","volume":"11","author":"WT van Haaften","year":"2020","unstructured":"van Haaften WT, Mortensen JH, Dige AK, Gr\u00f8nb\u00e6k H, Hvas CL, Bay-Jensen AC, et al. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn\u2019s Disease: A Pilot Study. Clin Transl Gastroenterol. 2020;11:e00217.","journal-title":"Clin Transl Gastroenterol"},{"key":"2967_CR13","doi-asserted-by":"crossref","unstructured":"Bay-Jensen AC, Madsen S, Gehring K, Musa K, Karsdal M. Rheumatoid arthritis is driven not only by inflammation but also fibrogenesis. Ann Rheum Dis. 2021;8(Supp. 1):AB0067.","DOI":"10.1136\/annrheumdis-2021-eular.3619"},{"key":"2967_CR14","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00296-011-2237-8","volume":"32","author":"AC Bay-Jensen","year":"2012","unstructured":"Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int. 2012;32:3565\u201372.","journal-title":"Rheumatol Int"},{"key":"2967_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/adt.2017.820","volume":"16","author":"JMB Sand","year":"2018","unstructured":"Sand JMB, Lamy P, Juhl P, Siebuhr AS, Iversen LV, Nawrocki A, et al. Development of a Neo-Epitope Specific Assay for Serological Assessment of Type VII Collagen Turnover and Its Relevance in Fibroproliferative Disorders. Assay Drug Dev Technol. 2018;16:123\u201331.","journal-title":"Assay Drug Dev Technol"},{"key":"2967_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-016-1040-z","volume":"18","author":"NS Gudmann","year":"2016","unstructured":"Gudmann NS, Munk HL, Christensen AF, Ejstrup L, S\u00f8rensen GL, Loft AG, et al. Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis. Arthritis Res Ther. 2016;18:141.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2967_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2474-15-309","volume":"15","author":"Y He","year":"2014","unstructured":"He Y, Siebuhr AS, Brandt-hansen NU, Wang J, Su D, Zheng Q, et al. Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. BMC Musculoskelet Disord. 2014;15(1):1\u201310.","journal-title":"BMC Musculoskelet Disord"},{"key":"2967_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0185855","volume":"12","author":"JH Mortensen","year":"2017","unstructured":"Mortensen JH, Manon-Jensen T, Jensen MD, H\u00e4gglund P, Klinge LG, Kjeldsen J, et al. Ulcerative colitis, Crohn\u2019s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn\u2019s disease. PLoS One. 2017;12:1\u201316.","journal-title":"PLoS One"},{"key":"2967_CR19","first-page":"358","volume":"37","author":"AS Siebuhr","year":"2019","unstructured":"Siebuhr AS, Hu\u0161akov\u00e1 M, Forejtov\u00e1 S, Zegzulkov\u00e1 K, Tom\u010dik M, Urbanov\u00e1 M, et al. Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clin Exp Rheumatol. 2019;37:358\u201366.","journal-title":"Clin Exp Rheumatol"},{"key":"2967_CR20","first-page":"371","volume":"30","author":"H Skj\u00f8t-Arkil","year":"2012","unstructured":"Skj\u00f8t-Arkil H, Schett G, Zhang C, Larsen DV, Wang Y, Zheng Q, et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2012;30:371\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"2967_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.37843","volume":"65","author":"AC Bay-jensen","year":"2013","unstructured":"Bay-jensen AC, Karsdal MA, Vassiliadis E, Wichuk S, Marcher-mikkelsen K, Lories R, et al. Circulating Citrullinated Vimentin Fragments Reflect Disease Burden in Ankylosing Spondylitis and Have Prognostic Capacity for Radiographic Progression. Arthritis Rheum. 2013;65:972\u201380.","journal-title":"Arthritis Rheum"},{"key":"2967_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ard.2009.111187","volume":"69","author":"SJ Pedersen","year":"2010","unstructured":"Pedersen SJ, S\u00f8rensen IJ, Hermann KGA, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor \u03b1 inhibitors. Ann Rheum Dis. 2010;69:1065\u201371.","journal-title":"Ann Rheum Dis"},{"key":"2967_CR23","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, S\u00f8rensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors. Ann Rheum Dis. 2011;70:1375\u201381.","journal-title":"Ann Rheum Dis"},{"key":"2967_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/art.10883","volume":"48","author":"J Braun","year":"2003","unstructured":"Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003;48:1126\u201336.","journal-title":"Arthritis Rheum"},{"key":"2967_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P MacHado","year":"2011","unstructured":"MacHado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"2967_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","volume":"8","author":"MK Tuck","year":"2009","unstructured":"Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, et al. Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group. J Proteome Res. 2009;8:113\u20137.","journal-title":"J Proteome Res"},{"key":"2967_CR27","doi-asserted-by":"publisher","first-page":"e24753","DOI":"10.1371\/journal.pone.0024753","volume":"6","author":"SS Veidal","year":"2011","unstructured":"Veidal SS, Karsdal MA, Vassiliadis E, Nawrocki A, Larsen MR, Nguyen QHT, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay. PLoS One. 2011;6:e24753.","journal-title":"PLoS One"},{"key":"2967_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clinbiochem.2011.01.001","volume":"44","author":"AC Bay-Jensen","year":"2011","unstructured":"Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem. 2011;44:423\u20139.","journal-title":"Clin Biochem"},{"key":"2967_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.clinbiochem.2010.03.012","volume":"43","author":"N Barascuk","year":"2010","unstructured":"Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899\u2013904.","journal-title":"Clin Biochem"},{"key":"2967_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/apt.13819","volume":"44","author":"MJ Nielsen","year":"2016","unstructured":"Nielsen MJ, Karsdal MA, Kazankov K, Gr\u00f8nb\u00e6k H, Krag A, Leeming DJ, et al. Fibrosis is not just fibrosis \u2013 basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Aliment Pharmacol Ther. 2016;44:1242\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"2967_CR31","first-page":"303","volume":"5","author":"MJ Nielsen","year":"2013","unstructured":"Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303\u201315.","journal-title":"Am J Transl Res"},{"key":"2967_CR32","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.clinbiochem.2010.07.025","volume":"43","author":"DJ Leeming","year":"2010","unstructured":"Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. Clin Biochem. 2010;43:1249\u201356.","journal-title":"Clin Biochem"},{"key":"2967_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.clinbiochem.2013.04.012","volume":"46","author":"S Sun","year":"2013","unstructured":"Sun S, Karsdal MA, Bay-jensen AC, S\u00f8rensen MG, Zheng Q, Dziegiel MH, et al. The development and characterization of an ELISA speci fi cally detecting the active form of cathepsin K. Clin Biochem. 2013;46:1601\u20136.","journal-title":"Clin Biochem"},{"key":"2967_CR34","doi-asserted-by":"publisher","first-page":"e84934","DOI":"10.1371\/journal.pone.0084934","volume":"8","author":"JM Sand","year":"2013","unstructured":"Sand JM, Larsen L, Hogaboam C, Martinez F, Han M, R\u00f8ssel Larsen M, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis--validation of two novel biomarker assays. PLoS One. 2013;8:e84934.","journal-title":"PLoS One"},{"key":"2967_CR35","doi-asserted-by":"crossref","unstructured":"Maksymowych WP. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol. 2019:305\u201325.","DOI":"10.3389\/fimmu.2019.00305"},{"key":"2967_CR36","doi-asserted-by":"crossref","unstructured":"Schett G. Bone formation versus bone: Resorption in ankylosing spondylitis. Adv Exp Med Biol. 2009;114\u201321.","DOI":"10.1007\/978-1-4419-0298-6_8"},{"key":"2967_CR37","doi-asserted-by":"crossref","unstructured":"De Vlam K. Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2010:671\u201382.","DOI":"10.1016\/j.berh.2010.05.009"},{"key":"2967_CR38","doi-asserted-by":"publisher","first-page":"26522","DOI":"10.1074\/jbc.272.42.26522","volume":"272","author":"H-J Kuo","year":"1997","unstructured":"Kuo H-J, Maslen CL, Keene DR, Glanville RW. Type VI Collagen Anchors Endothelial Basement Membranes by Interacting with Type IV Collagen* Downloaded from. J Biol Chem. 1997;272:26522\u20139.","journal-title":"J Biol Chem"},{"key":"2967_CR39","first-page":"3525","volume":"128","author":"M Cescon","year":"2015","unstructured":"Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015;128:3525\u201331.","journal-title":"J Cell Sci"},{"key":"2967_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.matbio.2011.03.002","volume":"30","author":"JF Groulx","year":"2011","unstructured":"Groulx JF, Gagn\u00e9 D, Benoit YD, Martel D, Basora N, Beaulieu JF. Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. 2011;30:195\u2013206.","journal-title":"Matrix Biol"},{"key":"2967_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/apt.12820","volume":"40","author":"MA Karsdal","year":"2014","unstructured":"Karsdal MA, Krarup H, JMB S, Christensen PB, Gerstoft J, Leeming DJ, et al. The efficacy of biomarkers in chronic fibroproliferative diseases - Early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther. 2014;40:233\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"2967_CR42","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar4266","volume":"15","author":"AS Siebuhr","year":"2013","unstructured":"Siebuhr AS, Bay-jensen AC, Leeming DJ, Plat A, Byrjalsen I, Christiansen C, et al. Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther. 2013;15:R86.","journal-title":"Arthritis Res Ther"},{"key":"2967_CR43","doi-asserted-by":"publisher","first-page":"6000648","DOI":"10.1136\/rmdopen-2018-000648","volume":"4","author":"AS Siebuhr","year":"2018","unstructured":"Siebuhr AS, Van Der Heijde D, Bay-Jensen AC, Karsdal MA, Landew\u00e9 R, Van Tubergen A, et al. Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix? RMD Open. 2018;4:6000648.","journal-title":"RMD Open"},{"key":"2967_CR44","doi-asserted-by":"publisher","first-page":"102760","DOI":"10.1016\/j.autrev.2021.102760","volume":"20","author":"SS Groen","year":"2021","unstructured":"Groen SS, Sinkeviciute D, Bay-Jensen AC, Thudium CS, Karsdal MA, Thomsen SF, et al. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev. 2021;20:102760.","journal-title":"Autoimmun Rev"},{"key":"2967_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","volume":"75","author":"OS Ademowo","year":"2016","unstructured":"Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2016;75:234\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2967_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11914-017-0358-z","volume":"15","author":"B Zhao","year":"2017","unstructured":"Zhao B. TNF and Bone Remodeling. Curr Osteoporos Rep. 2017;15:126\u201334.","journal-title":"Curr Osteoporos Rep"},{"key":"2967_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00223-013-9764-0","volume":"94","author":"S Wythe","year":"2014","unstructured":"Wythe S, Nicolaidou V, Horwood N. Cells of the immune system orchestrate changes in bone cell function. Calcif Tissue Int. 2014;94:98\u2013111.","journal-title":"Calcif Tissue Int"},{"key":"2967_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1186\/s12891-020-03804-2","volume":"21","author":"CS Thudium","year":"2020","unstructured":"Thudium CS, Nielsen SH, Sardar S, Mobasheri A, Evert Van Spil W, Lories R, et al. Bone phenotypes in rheumatology-there is more to bone than just bone. BMC Misculoskeletet Disord. 2020;21:789.","journal-title":"BMC Misculoskeletet Disord"},{"key":"2967_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jbspin.2019.04.006","volume":"87","author":"K Aouad","year":"2020","unstructured":"Aouad K, Ziade N, Baraliakos X. Structural progression in axial spondyloarthritis. Jt Bone Spine. 2020;87:131\u20136.","journal-title":"Jt Bone Spine"},{"key":"2967_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2003.012211","volume":"63","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Radstake TRD, Van Der Heijden A, Van Mansum MAM, Dieteren C, De Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis. 2004;63:373\u201381.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02967-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02967-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02967-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:05:15Z","timestamp":1671793515000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02967-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2967"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02967-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional scientific ethical committee (reference number H-KF-02-050\/04) and conducted in accordance with the Helsinki declaration. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHN, SS, ACBJ, and MAK are full-time employees at Nordic Bioscience A\/S. Nordic Bioscience is a privately-owned, small\u2013medium size enterprise (SME) partly focused on the development of biomarkers. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript. SHN, MAK, and ACBJ hold stocks in Nordic Bioscience A\/S. UW has nothing to disclose. AGL has received research support, consultancy fees, and\/or speakers fees from AbbVie, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. M\u00d8 has received research grants from Abbvie, Amgen, BMS, Merck, Celgene, and Novartis, and speaker and\/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and UCB. SJP has been an advisory board member for AbbVie and Novartis; received research support from AbbVie, MSD, and Novartis; and received speaker fees from MSD, Pfizer, AbbVie, Novartis, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}